BACKGROUND: The NLST (National Lung Screening Trial) showed reduced lung cancer mortality in high-risk participants (smoking history of ≥30 pack-years) aged 55 to 74 years who were randomly assigned to screening with low-dose computed tomography (LDCT) versus those assigned to chest radiography. An advisory panel recently expressed reservations about Medicare coverage of LDCT screening because of concerns about performance in the Medicare-aged population, which accounted for only 25% of the NLST participants. OBJECTIVE: To examine the results of the NLST LDCTgroup by age (Medicare-eligible vs. <65 years). DESIGN: Secondary analysis of a group from a randomized trial (NCT00047385). SETTING: 33 U.S. screening centers. PATIENTS: 19 612 participants aged 55 to 64 years (under-65 cohort) and 7110 participants aged 65 to 74 years (65+ cohort) at randomization. INTERVENTION: 3 annual rounds of LDCT screening. MEASUREMENTS: Demographics, smoking and medical history, screening examination adherence and results, diagnostic follow-up procedures and complications, lung cancer diagnoses, treatment, survival, and mortality. RESULTS: The aggregate false-positive rate was higher in the 65+ cohort than in the under-65 cohort (27.7% vs. 22.0%; P < 0.001). Invasive diagnostic procedures after false-positive screening results were modestly more frequent in the older cohort (3.3% vs. 2.7%; P = 0.039). Complications from invasive procedures were low in both groups (9.8% in the under-65 cohort vs. 8.5% in the 65+ cohort). Prevalence and positive predictive value (PPV) were higher in the 65+ cohort (PPV, 4.9% vs. 3.0%). Resection rates for screen-detected cancer were similar (75.6% in the under-65 cohort vs. 73.2% in the 65+ cohort). Five-year all-cause survival was lower in the 65+ cohort (55.1% vs. 64.1%; P = 0.018). LIMITATION: The oldest screened patient was aged 76 years. CONCLUSION:NLST participants aged 65 years or older had a higher rate of false-positive screening results than those younger than 65 years but a higher cancer prevalence and PPV. Screen-detected cancer was treated similarly in the groups. PRIMARY FUNDING SOURCE: National Institutes of Health.
RCT Entities:
BACKGROUND: The NLST (National Lung Screening Trial) showed reduced lung cancer mortality in high-risk participants (smoking history of ≥30 pack-years) aged 55 to 74 years who were randomly assigned to screening with low-dose computed tomography (LDCT) versus those assigned to chest radiography. An advisory panel recently expressed reservations about Medicare coverage of LDCT screening because of concerns about performance in the Medicare-aged population, which accounted for only 25% of the NLST participants. OBJECTIVE: To examine the results of the NLST LDCT group by age (Medicare-eligible vs. <65 years). DESIGN: Secondary analysis of a group from a randomized trial (NCT00047385). SETTING: 33 U.S. screening centers. PATIENTS: 19 612 participants aged 55 to 64 years (under-65 cohort) and 7110 participants aged 65 to 74 years (65+ cohort) at randomization. INTERVENTION: 3 annual rounds of LDCT screening. MEASUREMENTS: Demographics, smoking and medical history, screening examination adherence and results, diagnostic follow-up procedures and complications, lung cancer diagnoses, treatment, survival, and mortality. RESULTS: The aggregate false-positive rate was higher in the 65+ cohort than in the under-65 cohort (27.7% vs. 22.0%; P < 0.001). Invasive diagnostic procedures after false-positive screening results were modestly more frequent in the older cohort (3.3% vs. 2.7%; P = 0.039). Complications from invasive procedures were low in both groups (9.8% in the under-65 cohort vs. 8.5% in the 65+ cohort). Prevalence and positive predictive value (PPV) were higher in the 65+ cohort (PPV, 4.9% vs. 3.0%). Resection rates for screen-detected cancer were similar (75.6% in the under-65 cohort vs. 73.2% in the 65+ cohort). Five-year all-cause survival was lower in the 65+ cohort (55.1% vs. 64.1%; P = 0.018). LIMITATION: The oldest screened patient was aged 76 years. CONCLUSION: NLST participants aged 65 years or older had a higher rate of false-positive screening results than those younger than 65 years but a higher cancer prevalence and PPV. Screen-detected cancer was treated similarly in the groups. PRIMARY FUNDING SOURCE: National Institutes of Health.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Denise R Aberle; Christine D Berg; William C Black; Timothy R Church; Richard M Fagerstrom; Barbara Galen; Ilana F Gareen; Constantine Gatsonis; Jonathan Goldin; John K Gohagan; Bruce Hillman; Carl Jaffe; Barnett S Kramer; David Lynch; Pamela M Marcus; Mitchell Schnall; Daniel C Sullivan; Dorothy Sullivan; Carl J Zylak Journal: Radiology Date: 2010-11-02 Impact factor: 11.105
Authors: Carlos M Mery; Anastasia N Pappas; Raphael Bueno; Yolonda L Colson; Philip Linden; David J Sugarbaker; Michael T Jaklitsch Journal: Chest Date: 2005-07 Impact factor: 9.410
Authors: Benjamin D Kozower; Shubin Sheng; Sean M O'Brien; Michael J Liptay; Christine L Lau; David R Jones; David M Shahian; Cameron D Wright Journal: Ann Thorac Surg Date: 2010-09 Impact factor: 4.330
Authors: Stephen M Cattaneo; Bernard J Park; Andrew S Wilton; Venkatraman E Seshan; Manjit S Bains; Robert J Downey; Raja M Flores; Nabil Rizk; Valerie W Rusch Journal: Ann Thorac Surg Date: 2008-01 Impact factor: 4.330
Authors: Inga S Grills; Victor S Mangona; Robert Welsh; Gary Chmielewski; Erika McInerney; Shannon Martin; Jennifer Wloch; Hong Ye; Larry L Kestin Journal: J Clin Oncol Date: 2010-01-11 Impact factor: 44.544
Authors: Alissa K Greenberg; Feng Lu; Judith D Goldberg; Ellen Eylers; Jun-Chieh Tsay; Ting-An Yie; David Naidich; Georgeann McGuinness; Harvey Pass; Kam-Meng Tchou-Wong; Doreen Addrizzo-Harris; Abraham Chachoua; Bernard Crawford; William N Rom Journal: PLoS One Date: 2012-07-02 Impact factor: 3.240
Authors: Joshua A Roth; Sean D Sullivan; Bernardo H L Goulart; Arliene Ravelo; Joanna C Sanderson; Scott D Ramsey Journal: J Oncol Pract Date: 2015-05-05 Impact factor: 3.840
Authors: Nichole T Tanner; Lin Dai; Brett C Bade; Mulugeta Gebregziabher; Gerard A Silvestri Journal: Am J Respir Crit Care Med Date: 2017-09-01 Impact factor: 21.405
Authors: Tricia L Larose; Florence Guida; Anouar Fanidi; Arnulf Langhammer; Kristian Kveem; Victoria L Stevens; Eric J Jacobs; Stephanie A Smith-Warner; Edward Giovannucci; Demetrius Albanes; Stephanie J Weinstein; Neal D Freedman; Ross Prentice; Mary Pettinger; Cynthia A Thomson; Qiuyin Cai; Jie Wu; William J Blot; Alan A Arslan; Anne Zeleniuch-Jacquotte; Loic Le Marchand; Lynne R Wilkens; Christopher A Haiman; Xuehong Zhang; Meir J Stampfer; Allison M Hodge; Graham G Giles; Gianluca Severi; Mikael Johansson; Kjell Grankvist; Renwei Wang; Jian-Min Yuan; Yu-Tang Gao; Woon-Puay Koh; Xiao-Ou Shu; Wei Zheng; Yong-Bing Xiang; Honglan Li; Qing Lan; Kala Visvanathan; Judith Hoffman Bolton; Per Magne Ueland; Øivind Midttun; Neil Caporaso; Mark Purdue; Howard D Sesso; Julie E Buring; I-Min Lee; J Michael Gaziano; Jonas Manjer; Hans Brunnström; Paul Brennan; Mattias Johansson Journal: Int J Epidemiol Date: 2018-12-01 Impact factor: 7.196